European Notebook: Accelerated Ebola Reviews; EMA Remains In Health Directorate; Ireland’s Patent Box
EMA expert group will advise Ebola developers and agency will accept rolling submissions; Irish aims to lure research-based firms with patent box, while Swedish pharma stakeholders call for investments and policy changes to bring back innovative companies.
You may also be interested in...
FDA expects few people would get the disease in the U.S., but many could receive a vaccine.
The spread of Ebola to Europe is prompting regulators and industry to explore in more detail adaptive licensing pathways to speed access to potentially life-saving drugs.
U.K. biotech companies lead Europe in terms of funds raised and products in development in the first half of 2014, but other countries in the region are not far behind.